Archives of Dermatological Research最新文献

{"title":"The potential impact of ACOG guideline changes on genital melanoma detection rates in females: a retrospective cross-sectional analysis and implications for clinical practice","authors":"Kritin K. Verma,&nbsp;Danita Mathew,&nbsp;Mary Fitzgibbon,&nbsp;Daniel P. Friedmann,&nbsp;Ethan Matthew,&nbsp;Michelle B. Tarbox,&nbsp;Theodore Rosen","doi":"10.1007/s00403-025-03960-2","DOIUrl":"10.1007/s00403-025-03960-2","url":null,"abstract":"<div><p>Genital melanoma (GM) is a rare but aggressive cancer that accounts for less than 5% of vaginal cancers and 0.2–0.8% of all melanomas in the United States. The 2018 American College of Obstetricians and Gynecologists (ACOG) guidelines reduced routine pelvic exams for women aged 65 and older, raising concerns about later-stage GM diagnosis, worse survival rates, and potential underreporting. This study investigated the impact of these guideline changes on female GM detection rates through a cross-sectional analysis of female patients aged 18 and older in the All of Us database from 2012 to 2023. The analysis focused on melanoma in-situ (MIS) of the vulva using ICD-10-CM code D03.8 to calculate prevalence and incidence. The study identified 16 cases of vulvar MIS (0.006%, 95% CI [0.004-0.010%]) with a mean age of 64.6 ± 12.4 years at diagnosis. Prevalence peaked in the 61–70 age group (0.014%, 95% CI [0.000-0.029%]), with white patients showing the highest prevalence (0.009%, 95% CI [0.004-0.015%]). The overall incidence was 5.37 cases per million women per year. However, a decreasing trend was observed, with no cases reported between 2021 and 2023. This decline in reported cases may be linked to the 2018 ACOG guideline changes, potentially leading to later-stage diagnoses and poor outcomes. The study’s limitations include the inability to calculate yearly incidence due to lack of annual enrollment data and the absence of staging information. The findings suggest a potential connection between the ACOG guideline modifications and GM detection rates. While current incidence rates are similar to or higher than those before the 2018 changes, the decline in routine pelvic exams may contribute to later-stage diagnoses and poor outcomes. The absence of diagnosed GM cases in the past three years is particularly concerning and may reflect delayed effects of infrequent screening. Increased awareness, improved screening practices, and additional research are necessary to fully understand the impact of the 2018 ACOG guideline changes on GM diagnosis and treatment. Healthcare providers should consider performing yearly pelvic examinations, especially for patients over 65, while educating patients on early self-detection of GM.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143446454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of DLQI and Skindex-16 for assessing quality of life in patients with cellulitis","authors":"James Choe,&nbsp;Allison Yan,&nbsp;Ahana Gaurav,&nbsp;Eric Xia,&nbsp;Nora Bensellam,&nbsp;Dev R. Sahni,&nbsp;Arash Mostaghimi,&nbsp;John S. Barbieri","doi":"10.1007/s00403-025-03948-y","DOIUrl":"10.1007/s00403-025-03948-y","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding it, a way for the reduction of contact dermatitis and its costs","authors":"M. Felizardo,&nbsp;E. B. Dias","doi":"10.1007/s00403-025-03972-y","DOIUrl":"10.1007/s00403-025-03972-y","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The suture effect of butterfly suture combined with the looped, broad, and deep buried suture in patients with pigmented naevus receiving surgery excision","authors":"Fang Wu,&nbsp;Yan Tian,&nbsp;Fangfang Wang,&nbsp;Wenke Li,&nbsp;Yanmei Hu,&nbsp;Qiuyu Yang,&nbsp;Yuhang Sun","doi":"10.1007/s00403-025-03957-x","DOIUrl":"10.1007/s00403-025-03957-x","url":null,"abstract":"<div><p>This study aims to explore the suture effectiveness of butterfly suture combined the looped, broad, and deep buried suture (butterfly tension-reducing suture) in patients with pigmented naevus. A retrospective analysis of patients with pigmented naevus from January 2021 to December 2022 were performed. Patients were divided into: (1) control group that received routine suture; (2) observation group receiving butterfly tension-reducing suture. The ratio of scar area to the naevus area, the scar width and the incision complication were investigated. Vancouver Scar Scale scores of patients (VSS), Patient Scar Assessment Scale (PSAS) and the Observer Scar Assessment Scale (OSAS) at pre-operation and 6 months after surgery were compared. Logistic regression analysis was used for the risk factor analysis of post-operative scars. The study included 34 in control group and 41 in observation group. Observation group showed a lower incidence of incision complication and smaller scar width. At 6 months after surgery, VSS items showed statistical changes between the control and observation group, including pigmentation, vascularity, pliability, height, and total opinion. Using PSAS, observation group showed lower scores in color, stiffness, thickness, irregularity, pain, itch, and overall opinion as compared to control group. There were significant decreases in OSAS items of the observation group compared to the control group, including vascularity, thickness, pigmentation, pliability, relief, and overall opinion. Suture method and incision complication were the risk factors of post-operative scars. Butterfly tension-reducing suture improves aesthetics and prognosis in pigmented naevus patients by inhibiting extension excessive tension.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic and regional disparities in U.S. adult mortality due to cutaneous lupus erythematosus: insights from a CDC wonder analysis (1999–2020)","authors":"Sophia Ahmed,&nbsp;Syed Saad Ul Hassan,&nbsp;Sameen Tahira,&nbsp;Hira Saleem Raza,&nbsp;Muhammad Asfandyar Nadir,&nbsp;Mohammad Ashraf","doi":"10.1007/s00403-025-03926-4","DOIUrl":"10.1007/s00403-025-03926-4","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143438642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between rosacea, anxiety, and depression: a bidirectional two-sample Mendelian randomization study","authors":"Yu Liu,&nbsp;Wei Shi","doi":"10.1007/s00403-025-03800-3","DOIUrl":"10.1007/s00403-025-03800-3","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic effect of bosentan on 2, 4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis mouse model","authors":"Alhasan Haitham Habbas,&nbsp;Ahmed Rahma Abu-Raghif,&nbsp;Hayder Ridha-Salman,&nbsp;Muataz Naeem Hussein","doi":"10.1007/s00403-025-03955-z","DOIUrl":"10.1007/s00403-025-03955-z","url":null,"abstract":"<div><p>Eczematous or atopic dermatitis (AD) is a chronic autoinflammatory skin disorder distinguished by severe itching, scratching, and erosion. Bosentan is an endothelin receptor antagonist with improved immunomodulatory and anti-inflammatory actions. This study aimed to assess the efficiency of topical bosentan in alleviating a 2, 4-dinitrochlorobenzene (DNCB)-induced mouse model of AD. 50 Swiss albino mice were haphazardly grouped into 5 teams of 10 each. The first week of the experiment involved DNCB sensitization on back skin mice, preceding a four-week DNCB challenge to induce AD-like skin inflammation. The control group gets no treatment. The induction group administered DNCB only. Starting two hours after the second sensitization, the vehicle group received topical vehicle solution, the bosentan group received 5% bosentan ointment, and the tacrolimus group received 0.1% tacrolimus ointment once daily for a period of four weeks. Topical bosentan markedly mitigated DNCB-aggravated AD-like skin lesions, as displayed by decreased total dermatitis scores and lowering the upregulated counts of total leukocytes, neutrophils, lymphocytes, monocytes, and eosinophils. Additionally, bosentan dramatically alleviated interleukin (IL)-4 and IL-13 immunohistochemistry scores, as well as IL-1β, IL-6, IL-17, TNFα, and IFN-γ epidermal levels. In conclusion, Bosentan treatment also significantly diminished levels of immunoglobulin E (IgE) and oxidative biomarker malondialdehyde (MDA) and histopathology scores, notably epidermal thickness and inflammation. Bosentan mitigates the severity of DNCB-induced AD-like skin inflammation, possibly owing to its potent anti-inflammatory and immunomodulatory properties.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143438641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk in vitiligo: time for integration of clinical evaluation and echocardiography in management of patients?","authors":"Zeinab Aryanian,&nbsp;Ahmadreza Mozaffari,&nbsp;Safoura Shakoei,&nbsp;Ifa Etesami,&nbsp;Nafiseh Esmaeli,&nbsp;Mohammad Reza Eftekhari,&nbsp;Parvaneh Hatami","doi":"10.1007/s00403-025-03917-5","DOIUrl":"10.1007/s00403-025-03917-5","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bidirectional Mendelian Randomization identifies plasma proteins associated with urticaria risk","authors":"Xu Zhu,&nbsp;Wenzhong Wu","doi":"10.1007/s00403-025-03927-3","DOIUrl":"10.1007/s00403-025-03927-3","url":null,"abstract":"<div><p>Urticaria is a prevalent autoimmune skin disorder characterized by localized wheals and intense pruritus, significantly impairing the quality of life for affected individuals. Previous research has indicated that plasma proteins may contribute to the pathogenesis of urticaria. However, these findings do not establish a causal relationship. To address this gap, we conducted a large-scale Mendelian randomization(MR) study of the plasma proteome. In this study, we employed a two-sample, bidirectional Mendelian randomization approach to evaluate the causal relationship between the plasma proteome and urticaria. Utilizing large, publicly available genome-wide association studies, we examined the association of 4907 plasma proteins with the risk of developing urticaria. To assess heterogeneity and horizontal pleiotropy, we applied Cochran's Q test, the MR-Egger intercept test, and the MR-PRESSO global test. Furthermore, a sensitivity analysis was conducted to evaluate the influence of individual single nucleotide polymorphisms on the MR findings. Additionally, we performed enrichment analysis and GeneMANIA analysis to identify and annotate the functions of the selected plasma protein genes and to determine associated genetic factors. In this study, we examined 4,907 plasma proteomes as exposures and urticaria as the outcome. The findings revealed significant associations for several proteins, including CHCHD10, HBB, GZMB, LILRB2, MICB, IL21, FTMT, JPH4, and ISOC1 with the risk of urticaria. Specifically, three plasma protein phenotypes were identified as protective factors: GZMB (odds ratio [OR] = 0.76, 95% confidence interval [CI] 0.65–0.88, <i>P</i> &lt; 0.001), MICB (OR = 0.82, 95% CI 0.76–0.89, <i>P</i> &lt; 0.001), and FTMT (OR = 0.79, 95% CI 0.74–0.83, <i>P</i> &lt; 0.001). Conversely, other plasma protein phenotypes were identified as risk factors for urticaria: CHCHD10 (OR = 2.68, 95% CI 1.54–4.67, <i>P</i> &lt; 0.001), HBB (OR = 1.21, 95% CI 1.08–1.36, <i>P</i> = 0.001), LILRB2 (OR = 1.08, 95% CI 1.04–1.12, <i>P</i> &lt; 0.001), IL21 (OR = 1.19, 95% CI 1.08–1.31, <i>P</i> &lt; 0.001), JPH4 (OR = 1.30, 95% CI 1.13–1.50, <i>P</i> &lt; 0.001), and ISOC1 (OR = 1.18, 95% CI 1.07–1.30, <i>P</i> &lt; 0.001). Additionally, reverse Mendelian randomization analysis indicated that urticaria was a risk factor for ISOC1 (OR = 0.93, 95% CI 0.86–0.99, <i>P</i> = 0.03). We identified a bidirectional causal relationship between ISOC1 and urticaria. This study successfully elucidated the causal relationship between plasma protein phenotypes and urticaria, contributing valuable information for understanding the pathophysiology of the condition. Furthermore, it offers new genetic insights that may inform the identification of potential therapeutic targets for urticaria.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143430911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysing efficacy of low-dose oral minoxidil, topical minoxidil, and platelet-rich plasma with topical minoxidil combination in patients with androgenetic alopecia: a randomized controlled observer blinded trial","authors":"P. Janaani,&nbsp;Keshavmurthy Vinay,&nbsp;Hitaishi Mehta,&nbsp;Vinod Kumar,&nbsp;Narender Kumar,&nbsp;Muthu Sendhil Kumaran","doi":"10.1007/s00403-025-03938-0","DOIUrl":"10.1007/s00403-025-03938-0","url":null,"abstract":"<div><p>Androgenetic alopecia (AGA) is commonly treated with topical minoxidil, while platelet-rich plasma (PRP) and oral minoxidil offer alternative options. To compare the efficacy and safety of low-dose oral minoxidil (group 1) (G1), topical minoxidil (group 2) (G2), and PRP with topical minoxidil (group 3) (G3) in AGA. Seventy-five participants were randomly assigned to three treatment groups (<i>n</i> = 25),. Clinical and videodermoscopic assessments were performed at pre-scheduled intervals over 32 weeks, which was completed by 60 patients. At 32 weeks, 25% of patients in groups 1 and 3, and 10% in group 2 showed one grade improvement in AGA severity (<i>p</i> = 0.62). The median percentage increase in terminal hair density was 47.5 in G1, 48 in G2, and 57 in G3 at week 32 favoring G3 over G1 (<i>p</i> = 0.03) and G2 (<i>p</i> = 0.02). Median percentage decrease in vellus hair density was 26 in G1, 21 in G2, and 19 in G3, favoring G1 over G3 (<i>p</i> = 0.03), All 3 groups demonstrated a significant decrease in hair diameter diversity by 32 weeks, with no intergroup variation. The major side effects noted in G1 were headaches (20%), dizziness (15%), and pedal edema (5%). Scalp itching and dryness was observed in 75% of patients after topical minoxidil. Transient pain was observed in all patients during PRP procedure, along with minimal bleeding and dizziness in 15% and 5% respectively. Side effects experienced in all 3 groups were mild and were tolerated by most of the patients. The study emphasizes low-dose oral minoxidil as an effective alternative to topical minoxidil and also suggests the benefits of combining topical minoxidil with PRP.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143423164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}